Characterization of FGD5 expression in primary breast cancers and lymph node metastases by Valla, Marit et al.
1 
 
Characterization of FGD5 expression in primary breast cancers and 
lymph node metastases 
Marit Valla1,2, Patricia G Mjønes2,3, Monica J Engstrøm1,4, Borgny Ytterhus2, Diana L Bordin2, 
Barbara van Loon2,3, Lars A Akslen5,6, Lars J Vatten1, Signe Opdahl1,2, Anna M Bofin2.  
 
1Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, 
Norwegian University of Science and Technology, 7491 Trondheim, Norway 
2Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, 
Norwegian University of Science and Technology, 7491 Trondheim, Norway 
3Department of Pathology, St. Olav’s Hospital, Trondheim University Hospital, 7006 
Trondheim, Norway 
4Department of Breast and Endocrine Surgery, St. Olav’s Hospital, Trondheim University 
Hospital, 7006 Trondheim, Norway 
5Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, 
5020 Bergen, Norway 




Norwegian University of Science and Technology, 
Faculty of Medicine and Health Sciences, 
Department of Clinical and Molecular Medicine, 
Postboks 8905, N-7491 Trondheim, Norway  
Phone: +47 72571894 
Email: marit.valla@ntnu.no 
 
Running Title: FGD5 protein expression in breast cancer  
2 
 
FGD5 amplification drives tumour cell proliferation, and is present in 9.5% of breast cancers. 
We describe FGD5 expression; assess associations between FGD5 amplification and FGD5 
expression; and assess FGD5 expression in relation to proliferation and prognosis. FGD5 
immunohistochemistry was done on primary tumours (n=829) and lymph node metastases 
(n=231) from a cohort of Norwegian patients. We explored associations between FGD5 
amplification, FGD5 expression, and proliferation, and analyzed the prognostic value of FGD5 
expression by estimating cumulative risks of death and hazard ratios (HR). We identified 
nuclear and cytoplasmic expression in 64% and 73% of primary tumours, respectively, and 
found an association between gene amplification and nuclear expression (p=0.02). The 
proportion of cases with FGD5 expression was higher in lymph node metastases, compared 
to primary tumours (p=0.004 for nuclear and p=0.001 for cytoplasmic staining). Neither 
proliferation nor prognosis was associated with FGD5 expression (age-adjusted HR 1.12 (95% 
CI 0.89-1.41) for nuclear expression; and 0.88 (95% CI 0.70-1.12) for cytoplasmic expression). 
FGD5 is expressed in a high proportion of breast cancers and lymph node metastases. There 
was a correlation between FGD5 amplification and nuclear expression, but no association 
between FGD5 expression and proliferation or prognosis. 
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INTRODUCTION 
Sustained proliferation is one of the hallmarks of cancer (1), and identification of genes that 
are essential for tumour cell proliferation could be important for prognostication and 
development of targeted treatment of cancer patients. A combined genomic approach has 
identified FGD5 (Faciogenital dysplasia 5) amplification as a driver of proliferation in breast 
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cancer (2). Using fluorescence in situ hybridization (FISH), we previously identified FGD5 
amplification in 9.5% of breast cancers, and found that FGD5 amplification was associated 
with higher tumour proliferation and a poorer prognosis (3). FGD5 is located on the short 
arm of chromosome 3 (4), and in our study of FGD5, we defined amplification as FGD5/CEP3 
ratio ≥2 and/or mean FGD5 copy number/tumour cell  ≥4 (3).  
FGD5 is a Rho guanine nucleotide exchange factor (Rho GEF). Rho GEFs activate Rho 
GTPases through replacement of GDP by GTP (5). Rho GTPases regulate the cytoskeleton (6, 
7) and are involved in cellular processes such as cell cycle progression (8), gene expression 
(9, 10) and cell movement (7). Furthermore, their activity has been linked to tumorigenesis 
(11), and overexpression has been demonstrated in breast cancer (12), with higher levels in 
high grade and highly proliferative tumours (13, 14). Some genes encoding Rho GEFs are 
classified as oncogenes (15, 16), and although rare, mutations in Rho GEF encoding genes 
have been identified in cancer (17-19). Upregulation of Rho GEFs may be present in a large 
proportion of breast cancers (20-22), and high expression is associated with poor 
differentiation (21) and poor outcome (23). Due to their role in cancer progression, Rho GEFs 
and Rho GTPases may be targets for therapy (23, 24).  
In the present study, we used tissue microarrays (TMA) from 829 primary breast 
cancers from a cohort of Norwegian breast cancer patients.(25) The aims of the study were: 
to describe FGD5 expression by immunohistochemistry (IHC) in primary breast cancers and 
lymph node metastases; to assess a possible association between FGD5 amplification and 
FGD5 IHC expression; and to assess a possible association between FGD5 expression, and 




MATERIALS AND METHODS 
 
Ethical considerations 
The study was approved by the Regional Committee for Medical and Health Sciences 
Research Ethics (REK, Midt-Norge, Norway, reference number 836/2009). 
 
Study population 
Between 1956 and 1959, a population-based survey for the early detection of breast cancer 
was carried out in three counties in Norway (26). We have studied breast cancers occurring 
among women from one county (Trøndelag), between 1961 and 2008 (25). The women were 
born between 1886 and 1928.  The Cancer Registry of Norway (27) provided information on 
incident cancer, and the Norwegian Cause of Death Registry supplied information on date 
and cause of death. During follow-up, 1379 breast cancers were diagnosed, and 909 were 
previously reclassified into molecular subtypes by means of IHC and in situ hybridization 
(ISH) (25).  
The majority of subtyped tumours (867/909) were included in TMAs, and in the 
present study, these were stained with FGD5 antibody. A total of 38 cases were excluded, 
due to insufficient amount (n=32) or poor quality (n=6) of tumour tissue. Thus, 829 tumours 
remained.  
Of the 829 cases, 293 had known lymph node metastases at diagnosis, and 233 of 
these were available in TMAs. Two cases were excluded due to insufficient amounts of 
tumour tissue. Thus, 231 cases were suitable for assessment of FGD5 expression in lymph 





All tumours were previously classified according to histopathological type and grade using 
current guidelines (28, 29) and molecular subtype (25). Briefly, TMAs were constructed using 
the Tissue Arrayer Minicore® 3 with TMA Designer2 software (Alphelys, 78370 Plaisir, France). 
Three 1 mm-in-diameter tissue cores from the periphery of the primary tumour and three 
cores from the lymph node metastases were assembled in recipient blocks. 
Immunohistochemical markers used for molecular subtyping included: oestrogen receptor 
(ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki67, 
cytokeratin 5 (CK5) and epidermal growth factor receptor (EGFR) (Table 1) (25). HER2 status 
was assessed using chromogenic in situ hybridization (CISH). A detailed description of marker 
assessment used in molecular subtyping is given in previous publications by our group (25, 
30). With regard to Ki67, assessment was done in hotspots, counting 500 tumour cells. 
Nuclear Ki67 staining was considered positive, regardless of staining intensity (31).  
From the TMAs, 4-μm thick sections were cut and mounted on Superfrost+ glass 
slides.  Sections were dried at 37°C overnight, and stored in the freezer at -20°C until use. 
FGD5 IHC was performed according to the manufacturer’s guidelines: Slides were heated at 
60°C for 1.5 hours, and pre-treated in a PT Link, Pre-Treatment Module for Tissue Specimens 
(Dako Denmark A/S, 2600 Glostrup, DK) with EnVision FLEX Target Retrieval Solution Low pH, 
DAKO DM829) at 97°C for 20 minutes. IHC using rabbit polyclonal FGD5 antibody (Table 2) 
was done in a DakoCytomation Autostainer Plus (Dako). Dako REAL™EnVision™ Detection 





Negative and positive controls were included. Normal breast tissue was used as a positive 
tissue control (Supplementary Figure 1).  For negative controls, we omitted the primary 
antibody in a section from normal breast and in a TMA section containing breast cancer 
tissue from our study cohort (Supplementary Figure 1 and 2). For isotype controls, we used a 
section from normal breast, and a TMA section containing breast cancer tissue from our 
study cohort (Supplementary Figure 1 and 3). Isotype control sections were compared to the 
corresponding FGD5 stained sections. Cytoplasmic staining was not present in the isotype 
control sections, however some cases had sporadic cells with faint nuclear staining. The 
isotype control (rabbit IgG, polyclonal, Table 2) was diluted in order to obtain the same 
protein concentration as the primary FGD5 antibody (32).  
 
Cell culture 
MCF-7 (human breast adenocarcinoma) cell line obtained from ATCC (Manassas, USA) were 
grown in EMEM (Life Technologies, Carlsbad, California, USA) with 0.01 mg/mL insulin (Life 
Technologies), 10% FCS (Life Technologies) and 1% penicillin/streptomycin (Life 
Technologies), in 5% CO2 atmosphere at 37°C. 
 
Immunoblotting 
For validation of FGD5 antibody specificity, we performed immunoblot analysis of MCF-7 
whole cell extracts (WCE) prepared according to a previously published protocol (33). 20 g 
of WCE was separated on NuPAGE 4-12% gradient Bis-Tris polyacrylamide gels (Invitrogen) 
and transferred to an Immobilon-FL membrane (Millipore) for subsequent immunoblotting. 
Upon blocking the membrane was incubated with primary antibodies targeting FGD5 and 
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tubulin. Primary antibodies were detected using infrared (IR) Dye-conjugated secondary 
antibodies IRDye® 800CW Goat anti-Mouse IgG and IRDye® 680RD Goat anti-Rabbit IgG 
(Table 2). The signal was visualized using direct IR fluorescence via the Odyssey Scanner, LI-
COR Biosciences. 
 
Scoring, reporting and classification of tumours 
Slides were assessed in a bright-field microscope, and for each case, the reported score was 
an average of all available TMA cylinders. Cytoplasmic FGD5 staining intensity (0 =no 
staining, 1 =weak, 2 =moderate, and 3 =strong staining) and the proportion of cells with 
cytoplasmic staining (0: no staining, 1: <10%, 2: 10-50%, and 3: >50%) were recorded. A 
staining index (SI) was calculated, multiplying intensity by proportion. SI 0-1 was considered 
negative, and SI ≥2 was considered positive. The proportion of tumour cells with positive 
nuclear staining was also recorded, irrespective of staining intensity. All IHC stains were 
assessed by two pathologists (MV and AMB or PGM) independently. Discrepant results were 
discussed, and consensus was reached. The REMARK criteria for tumour marker prognostic 
studies were followed.(34) 
 
Statistical analyses 
We used Pearson’s Chi-square test to assess differences in clinical and tumour 
characteristics across categories of FGD5 IHC staining; to compare proportions of FGD5 IHC 
staining across categories of FGD5 copy number status; and to compare FGD5 IHC staining in 
primary tumours and lymph node metastases. We also performed multivariate logistic 
regression to adjust for other tumour characteristics. Cumulative incidence of death from 
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breast cancer was estimated according to categories of FGD5 staining. In these analyses, 
death from other causes was considered a competing event, and Gray’s test was used to test 
for equality between cumulative incidence curves. We used Cox proportional hazards 
models to estimate hazard ratios (HRs) of death from breast cancer (with 95% confidence 
intervals (CIs)) according to FGD5 staining, censoring at time of death from other causes. 
Negative staining was used as the reference. Adjustments were made for other prognostic 
factors at baseline: age (≤49, 50-59, 60-64, 65-69, 70-74, ≥75 years), histological grade (1-3), 
and stage (I-IV). Adjustments were made for each factor separately, and all combined. No 
clear violations of proportionality were observed in log-minus-log plots. Stata version 13.1 






FGD5 expression and FGD5 copy number status in primary tumours 
Cytoplasmic FGD5 staining was present in a large proportion of tumours, and a SI ≥2 was 
identified in 73% of cases (Table 3, Fig. 1B). We found no clear associations between FGD5 
copy number status and cytoplasmic staining in the primary tumours (Table 4). With cut-offs 
of 1% and 10%, we identified positive nuclear FGD5 staining in 64% and 26% of cases, 
respectively (Table 3, Fig. 1A). There was an association between FGD5 copy number status 
and nuclear staining (1% cut-off), with a higher proportion of positive nuclei among 
amplified, compared to non-amplified cases (85% vs. 67%, p=0.02). With a cut-off of 10%, 
however, there was no association between FGD5 copy number status and nuclear staining. 
Positive cytoplasmic and nuclear staining of FGD5 was found in a high proportion of cases 
within all molecular subtypes (Table 3). For cytoplasmic staining,  SI>2 was found in 74% of 
Luminal A, 75% of Luminal B (HER2-), 70% of Luminal B (HER2+), 61% of HER2 type, 50% of 
5NP, and 81% of BP tumours, respectively.  After adjustment for other characteristics, the 
odds of positive cytoplasmic staining (SI>2) was highest for BP, and lowest for 5NP. For 
nuclear staining, the odds of FGD5 expression (≥1% or ≥10%) was highest in Luminal A 
tumours. Positive FGD5 staining in endothelial cells was observed (Fig. 1C). 
 
FGD5 expression in lymph node metastases 
A SI ≥2 was identified in 80 % of lymph node metastases (Table 5). Of all cases with SI <2 in 
the primary tumour, 68% had SI ≥2 in the corresponding lymph node metastases (p=0.001). 
Nuclear FGD5 staining was present in 92 % (1% cut-off) and 45 % (10% cut-off) of lymph 
node metastases. Among cases with negative nuclear staining (1% cut-off) in the primary 
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tumours, 85% had positive nuclear staining in the corresponding lymph node metastases 
(p=0.004). Correspondingly, with a 10 % cut-off, 38% of cases with negative nuclear staining 
in the primary tumours, had positive staining in the lymph node metastases (p<0.001).  
 
Immunoblotting 
Antibody specificity was validated by immunoblot analysis of three human breast cancer cell 
lines (MCF-7, T47-D and HCC1806), in which the most prominent band (61 kDa, Fig. 1D) 
corresponded to isoform 2 of FGD5 (Figure 1D) (35, 36). 
FGD5 and proliferation 
The distribution of Ki67 low/high (<15% vs. ≥15%) tumours was similar when FGD5 staining 
of primary tumours was categorized based on SI, or based on nuclear staining with a 1% cut-
off (p=0.27 and p=0.15, respectively, Table 3). The proportion of Ki67-high tumours was 
lower among cases with ≥10% FGD5-positive nuclei, compared to cases with <10% positive 
nuclei (37% vs. 47%, p=0.007). We found no clear differences in the number of mitoses in 
the primary tumours across categories of cytoplasmic or nuclear FGD5 staining. 
 
FGD5 IHC and prognosis 
We found similar cumulative risks of death from breast cancer when cases were subdivided 
based on SI status (SI <2 vs. ≥2, Gray’s test: p=0.36) and nuclear staining (1% cut-off, Gray’s 
test: p=0.62; 10% cut-off, Gray’s test: p=0.83) (Table 6). Cox regression analyses using 
negative staining as a reference confirmed this finding, and showed age-adjusted HR of 0.88 
(95% CI 0.70-1.12) for SI, 1.12 (95% CI 0.89-1.41) for nuclear staining at 1% cut-off, and 0.96 
(95% CI 0.74-1.24) for nuclear staining  at 10% cut-off. Adjustments for stage and histological 
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grade at diagnosis did not significantly change these estimates.  We also performed separate 
analyses for each molecular subtype and found no clear differences in prognosis across 




We identified FGD5 staining in the cytoplasm and nuclei in a large proportion of primary 
breast cancers and lymph node metastases. The proportion of cases with positive FGD5 
staining in lymph node metastases was markedly higher compared to the corresponding 
primary tumours. There was a positive association between FGD5 amplification status and 
nuclear staining at 1% cut-off in the primary tumours. However, neither proliferation nor 
prognosis was found to be associated with FGD5 expression.  
A strength of our study is the large number of cases with long-term follow-up data 
acquired from high quality national registries (27). Assessment of IHC was done by two 
pathologists independently, using predetermined criteria for evaluation. Discrepant results 
were discussed, and consensus was reached.  
Breast cancers included in this study were diagnosed between 1961 and 2008, and it 
is likely that preanalytical conditions have varied during the inclusion period, possibly 
influencing our results (37). However it has been shown in other studies that valuable results 
can be obtained using archival material (37, 38). 
 According to the Human Protein Atlas, a cytoplasmic staining pattern was expected  
(39). FGD5 is a new marker with no available guidelines for assessment, and for cytoplasmic 
staining, we used a staining index, where the intensity of staining was multiplied with the 
proportion of stained cells. This approach has been used for other markers (40-42). We 
regarded SI ≥2 as positive, similar to previous studies of other markers (25, 30, 40, 43). In 
addition, we observed nuclear staining in a large proportion of cases, and the proportion of 
stained nuclei, irrespective of staining intensity was recorded. Not including staining 
intensity in the assessment of nuclear markers is routine both for hormone receptors and 
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Ki67 in breast cancer (31, 44).  For nuclear staining, two different cut-off levels were used in 
the analyses.  
Gatza et al. found that FGD5 was amplified uniquely in highly proliferative luminal 
tumours, and that amplification of the gene was prognostic in luminal tumours (2). Their 
molecular subtyping was done by gene expression analysis, and luminal tumours were 
defined as all tumours that were not basal. We reclassified breast cancer tumours into six 
different molecular subtypes using surrogate IHC and ISH markers (25, 30). It has been 
shown that molecular subtyping by gene expression analysis is similar, but not identical to 
subtyping using surrogate markers (45-48). In our previous study, FGD5 copy number 
increase was identified within all molecular subtypes, and amplifications were found in all 
molecular subtypes except the 5NP. In the present study, we identified positive FGD5 
staining in a high proportion of cases within all molecular subtypes, with the highest 
proportion observed in the BP. Despite some differences in cytoplasmic and nuclear staining, 
we found no clear differences in prognostic value of FGD5 across subtypes.   
There was a positive association between FGD5 amplification and nuclear FGD5 
staining. For most cases in which nuclear FGD5 staining was identified, the percentage of 
positive nuclei was low (median value 4%).  
In breast cancer, amplification of the HER2 gene is strongly associated with 
overexpression of the HER2 protein (49). Therefore, in order to select patients for targeted 
anti-HER2 treatment, both ISH and IHC can be used (50, 51). However, studies of many other 
genes have demonstrated a poor correlation between gene copy number or mRNA 
expression, and protein level (14, 49, 52).  
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In this study, lack of correlation between FGD5 copy number and cytoplasmic staining 
was observed. While a correlation between gene copy number and mRNA levels has been 
indicated previously (2), for the samples included in this study this correlation has not been 
demonstrated so far. Lack of correlation between FGD5 copy number and cytoplasmic 
staining suggests that the amplified gene copy is potentially silenced. The amplified gene 
copy could have been translocated to a new region in the genome, and potentially silenced 
through mechanisms such as methylation. Further, since within FGD5 is encoded non-coding 
RNA (LOC105376963), the copy number increase does not only affect FGD5 expression, but 
could also result in altered expression of the non-coding RNA, potentially influencing other 
genes and/or other pathways.  
The lack of correlation between copy number and protein levels could reflect 
underlying biology, and our findings suggest that FGD5 affects proliferation in other ways 
than through its protein product. FGD5 protein has been described to exist in two isoforms, 
the longer 160kDa isoform 1 and shorter 61kDa isoform 2. Interestingly, the immunoblot 
analysis indicated presence of only shorter isoform 2 in the tested breast cancer cell line 
(Figure 1D).  It is however not possible to exclude that another isoform not detected by the 
antibody is present and potentially play a role in breast cancer cells. Since this is the first 
study of FGD5 expression in a cohort of breast cancer patients, our findings need to be 
validated in other cohorts. Further studies using other FGD5 antibodies or a proteomic 
approach would be of added value.    
The antibody used in the present study was a polyclonal Protein Epitope Signature 
Tag antibody (PrEST) (53) selected from the Human Protein Atlas (54, 55). PrESTs have 
similar specificity to monoclonal antibodies (53).  
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We found no clear association between FGD5 expression and prognosis in this study. 
However, we previously found strong associations between FGD5 amplification status and 
prognosis in the same cohort of breast cancer patients. Evidently, the role of FGD5 in breast 
cancer proliferation and prognosis is not yet clarified. FGD5 is classified as a RhoGEF, and 
these molecules are known to activate Rho GTPases, whose activity has been linked to 
cancer progression (8, 11-14). FGD5 is expressed in endothelial cells (56-60), and studies 
have demonstrated its presence in the plasma membrane (58, 60) and in the perinuclear 
region (58) of human umbilical vein endothelial cells (HUVECs). FGD5 can affect endothelial 
cell barriers through interactions with the Rho GTPase Cdc42 (60), and the latter has been 
identified as the selective binding partner for FGD5 (57). In a recent study, Cdc42 protein 
expression was identified in a large proportion of breast cancers, and cytoplasmic expression 
was associated with higher grade and higher Ki67 levels (61). A possible link between FGD5 
and angiogenesis has been suggested (57-59), and Rho GTPases such as Cdc42 are involved 
in angiogenesis through regulation of the cytoskeleton and organization of endothelial cells 
(62, 63). Interestingly, positive FGD5 staining in blood vessels was identified in our study, 
and thus, assessing whether FGD5 copy number status or FGD5 expression may be 
associated with tumour angiogenesis could provide valuable information on the role of FGD5 
in breast cancer development.  
 
In conclusion, we have demonstrated cytoplasmic and nuclear FGD5 staining in a 
large proportion of primary breast cancers and lymph node metastases. The proportion of 
FGD5 positive lymph nodes was higher compared to the corresponding primary tumours. 
There was an association between FGD5 amplification status and nuclear FGD5 staining, 
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Figure 1. FGD5 immunohistochemical staining in the nuclei (A) and cytoplasm (B) of tumour 
cells, and in blood vessels (arrows) (C). Scale bar = 50 µm. D) Immunoblot analysis using anti-
FGD5 rabbit polyclonal antibody (HPA019191, Sigma-Aldrich) on breast cancer cell lines 
(from the left; MCF7, T47-D, and HCC1806) showing a prominent band consistent with 




Table 1. Reclassification into molecular subtypes (25, 30). 
Molecular subtype Criteria for molecular subtype 
Luminal A ER and/or PR positive, HER2 negative, Ki67<15% 
Luminal B (HER2-) ER and/or PR positive, HER2 negative, Ki67≥15% 
Luminal B (HER2+) ER and/or PR positive, HER2 positive 
HER2 type ER and PR negative, HER2 positive 
Basal phenotype ER, PR and HER2 negative, CK5 and/or EGFR positive 
5 negative phenotype ER, PR, HER2, CK5, and EGFR negative 
Abbreviations: ER= oestrogen receptor, PR= progesterone receptor, HER2= human 












FGD5 HPA019191 Sigma-Aldrich 0.05 mg/ml                         1:40 b
FGD5 HPA019191 Sigma-Aldrich 0.05 mg/ml 1:500 c 
Rabbit IgG polyclonald Ab27478 Abcam 0.2 mg/ml 1:160 
Tubulin T9026 Sigma-Aldrich 4 mg/mL 1:000 
IRDye® 800CW  P/N 925-32210 LI-COR Biosciences 1 mg/mL 1:15000 
IRDye® 680RD  P/N 925-68071 LI-COR Biosciences 1 mg/mL 1:15000 
Abbreviations: FGD5= Faciogenital dysplasia 5. aComplete name and address of manufacturers: 
Sigma-Aldrich, St.Louis, USA; LI-COR Biosciences, Lincoln, Nebraska USA.  
bUsed for immunohistochemistry of primary tumours and lymph node metastases.  





Table 3. Characteristics of the study population according to FGD5 staining 
 Cytoplasmic staining, staining index (SI) Nuclear staining, 1% cut-off Nuclear staining, 10% cut-off  
SI <2 SI ≥ 2 OR (95% CI) <1% ≥1% OR (95% CI) <10% ≥10% OR (95% CI) Total 
Number of cases 227 (27) 602 (73) - 297 (36) 532 (64) - 616 (74) 213 (26) - 829 (100) 
Mean age at diagnosis (SD) 70.3 (11.2) 72.6 (10.0) - 71.2 (9.9) 72.5 (10.7) - 71.1 (10.5) 74.8 (9.6) - 72 (10.4) 
Mean follow-up, years (SD) 9.0 (8.7) 9.0 (7.7) - 9.9 (8.2) 8.5 (7.8) - 9.3 (8.3) 8.1 (7.1) - 9.0 (8.0) 
Breast cancer death 96 (42) 232 (39) - 117 (39) 211 (40) - 247 (40) 81 (38) - 328 (40) 
Death other causes 103 (45) 270 (45) - 133 (45) 240 (45) - 280 (45) 93 (44) - 373 (45) 
Grade, n (%)1           
    I 28 (12) 67 (11) 1 (ref) 29 (10) 66 (12) 1 (ref) 61 (10) 34 (16) 1 (ref) 95 (11) 
    II 107 (47) 333 (55) 1.41 (0.85-2.36) 162 (55) 278 (52) 0.78 (0.48-1.28) 323 (52) 117 (55) 0.66 (0.40-1.09) 440 (53) 
    III 92 (41) 202 (34) 0.93 (0.52-1.67) 106 (36) 188 (35) 1.11 (0.63-1.96) 232 (38) 62 (29) 0.73 (0.40-1.31) 294 (35) 
Chi2 test P=0.10  P=0.51  P=0.01   
Lymph node metastasis2           
    Yes 92 (41) 201 (33) 0.96 (0.60-1.55) 98 (33) 195 (37) 1.02 (0.66-1.58) 215 (35) 78 (37) 1.05 (0.65-1.70) 293 (35) 
    No 77 (34) 245 (41) 1 (ref) 111 (37) 211 (40) 1 (ref) 240 (39) 82 (39) 1 (ref) 322 (39) 
    Unknown lymph node status     58 (26) 156 (26) - 88 (30) 126 (24) - 161 (26) 53 (25) - 214 (26) 
Chi2 test P=0.03  P=0.79  P=0.74   
Tumour size2           
    ≤2 cm 78 (34) 294 (49) 1 (ref) 149 (50) 223 (42) 1 (ref) 291 (47) 81 (38) 1 (ref) 372 (45) 
    >2 ≤5 cm 30 (13) 70 (12) 0.68 (0.37-1.24) 24 (8) 76 (14) 2.06 (1.10-3.87) 48 (8) 52 (24) 4.32 (2.39-7.82) 100 (12) 
    >5 cm 1 (0) 8 (1) 0.82 (0.09-7.66) 0 (0) 9 (2) - 5 (1) 4 (2) - 9 (1) 
    Uncertain, but >2 cm 51 (23) 89 (15) 0.52 (0.28-0.96) 45 (15) 95 (18) 1.54 (0.85-2.80) 104 (17) 36 (17) 1.47 (0.75-2.89) 140 (17) 
    Uncertain 67 (30) 141 (23) - 79 (27) 129 (24) - 168 (27) 40 (19) - 208 (25) 
Chi2 test P=0.002  P=0.002  P<0.001   
Stage at diagnosis1           
    1 99 (44) 306 (51) 1 (ref) 159 (54) 246 (46) 1 (ref) 304 (50) 101 (47) 1 (ref) 405 (49) 
    2 101 (45) 227 (38) 0.75 (0.53-1.04) 111 (38) 217 (41) 1.33 (0.98-1.82) 238 (39) 90 (42) 1.32 (0.93-1.87) 328 (40) 
    3 13 (6) 37 (6) 0.95 (0.47-1.89) 12 (4) 38 (7) 2.09 (1.04-4.19) 38 (6) 12 (6) 0.95 (0.46-1.94) 50 (6) 
    4 13 (6) 28 (5) 0.67 (0.33-1.37) 11 (4) 30 (6) 1.94 (0.93-4.06) 31 (5) 10 (5) 1.14 (0.52-2.48) 41 (5) 
Chi2 test P=0.37  P=0.02  P=0.65   
Molecular subtype1           
    Luminal A 104 (46) 292 (49) 1 (ref) 121 (41) 275 (52) 1 (ref) 266 (43) 130 (61) 1 (ref) 396 (48) 
    Luminal B (HER2-) 56 (25) 169 (28) 1.28 (0.84-1.95) 84 (28) 141 (27) 0.67 (0.46-0.98) 169 (27) 56 (26) 0.74 (0.49-1.11) 225 (27) 
    Luminal B (HER2+) 19 (8) 44 (7) 1.04 (0.55-1.94) 32 (11) 31 (6) 0.37 (0.20-0.65) 58 (9) 5 (2) 0.18 (0.07-0.49) 63 (8) 
    HER2 type 22 (10) 34 (6) 0.80 (0.41-1.57) 22 (7) 34 (6) 0.51 (0.26-0.99) 45 (7) 11 (5) 0.58 (0.26-1.26) 56 (7) 
    5 negative phenotype 15 (7) 15 (3) 0.38 (0.17-0.81) 13 (4) 17 (3) 0.53 (0.25-1.16) 27 (4) 3 (1) 0.24 (0.07-0.81) 30 (4) 
27 
 
    Basal phenotype 11 (5) 48 (8) 2.16 (1.01-4.61) 25 (8) 34 (6) 0.45 (0.24-0.85) 51 (8) 8 (4) 0.31 (0.13-0.72) 59 (7) 
Chi2 test P=0.01  P=0.02  P<0.001   
Ki673           
    Ki67 <15% 133 (59) 327 (54) 1 (ref) 155 (52) 305 (57) 1 (ref) 325 (53) 135 (63) 1 (ref) 460 (55) 
    Ki67 ≥15% 94 (41) 275 (46) 1.61 (1.11-2.34) 142 (48) 227 (43) 0.79 (0.57-1.11) 291 (47) 78 (37) 0.80 (0.55-1.16) 369 (45) 
Chi2 test P=0.27  P=0.15  P=0.007   
Mitoses/10HPF4           
    ≤2 74 (33) 192 (32) 1 (ref) 96 (32) 170 (32) 1 (ref) 188 (31) 78 (37) 1 (ref) 266 (32) 
    >2 to  ≤6 42 (19) 138 (23) 1.27 (0.81-2.00) 64 (22) 116 (22) 1.19 (0.79-1.80) 136 (22) 44 (21) 0.90 (0.57-1.41) 180 (22) 
    >6 to ≤13 55 (24) 126 (21) 0.88 (0.56-1.38) 65 (22) 116 (22) 1.32 (0.85-2.03) 129 (21) 52 (24) 1.33 (0.84-2.12) 181 (22) 
    >13 56 (25) 146 (24) 1.05 (0.64-1.70) 72 (24) 130 (24) 1.54 (0.98-2.42) 163 (26) 39 (18) 0.96 (0.57-1.63) 202 (24) 
Chi2 test P=0.50  P=0.999  P=0.067   
Numbers are number of observations (%) unless otherwise specified. Abbreviations: SD= standard deviation, HER2= human epidermal growth factor receptor 2, HPF= high power fields.  
1 In the logistic regression analysis, mutual adjustments were made for age, grade, stage, and molecular subtype, as applicable.  
2 In the logistic regression analysis, mutual adjustments were made for age, grade, lymph node status, tumour size and molecular subtype, as applicable. 





Table 4. FGD5 copy number status and FGD5 immunohistochemical expression in primary tumours 
  FGD5 copy number status 





Ratio <2a Ratio ≥2b ≤2 >2 to <4 ≥4 
Ratio <2 and 
mean FGD5<4 



















index, n (%) 
        
    <2 22 (18) 62 (23) 5 (21) 31 (19) 54 (24) 4 (13) 84 (22) 5 (13) 
    ≥2 97 (82) 213 (77) 19 (79) 135 (81) 167 (76) 27 (87) 295 (78) 34 (87) 
    Chi2 test P=0.66 P=0.19 P=0.18 
Nuclear staining, n 
(%) 
        
    <1% 38 (32) 90 (33) 4 (17) 63 (38) 63 (29) 6 (19) 126 (33) 6 (15) 
    ≥1% 81 (68) 185 (67) 20 (83) 103 (62) 158 (71) 25 (81) 253 (67) 33 (85) 
    Chi2 test P=0.27 P=0.04 P=0.02 
Nuclear staining, n 
(%) 
        
    <10% 79 (66) 193 (70) 15 (63) 115 (69) 150 (68) 22 (71) 261 (69) 26 (67) 
    ≥10% 40 (34) 82 (30) 9 (38) 51 (31) 71 (32) 9 (29) 118 (31) 13 (33) 
    Chi2 test P=0.61 P=0.92 P=0.78 





Table 5. FGD5 cytoplasmic and nuclear staining in primary tumours and lymph node 
metastases 















Cytoplasmic staining index Negative (<2) Positive (≥2) Total 
    Negative (<2) 25 (32) 21 (14) 46  
    Positive (≥2) 52 (68) 133 (86) 185  
    Total 77  154  231  
Chi2 test P=0.001  
    
Nuclear staining 1% cut-off Negative (<1%) Positive (≥1%) Total 
    Negative (<1%) 11 (15) 7 (4) 18  
    Positive (≥1%) 61 (85) 152 (96) 213  
    Total 72  159  231  
Chi2 test P=0.004  
    
Nuclear staining 10% cut-off Negative (<10%) Positive (≥10%) Total 
    Negative (<10%) 103 (62) 23 (35) 126  
    Positive (≥10%) 63 (38) 42 (65) 105  
    Total 166  65  231  








Table 6. Absolute and relative risks of death from breast cancer according to cytoplasmic and nuclear immunohistochemical FGD5 staining  
 Cytoplasmic staining index Nuclear staining, 1% cut-off Nuclear staining, 10% cut-off 
 Negative (<2) Positive (≥2) Negative (<1%) Positive (≥1%) Negative (<10%) Positive (≥10%) 
       
Cum. risk (%) until 5 years 
after diagnosis (95% CI) 
27.6 (22.2-33.9) 23.9 (20.7-27.6) 23.0 (18.6-28.2) 26.0 (22.5-30.0) 25.0 (21.7-28.6) 24.8 (19.5-31.3) 
     P-value Gray’s test p=0.21 p=0.25 p=0.98 
       
Cum. risk (%) until 15 years 
after diagnosis (95% CI) 
41.8 (35.4-48.7) 37.5 (33.7-41.6) 37.7 (32.3-43.6) 39.3 (35.2-43.7) 38.8 (35.0-42.9) 38.1 (31.7-45.2) 
     P-value Gray’s test p=0.25 p=0.44 p=0.95 
       
HRa (95% CI) 1 (ref) 0.88 (0.69-1.11) 1 (ref) 1.14 (0.91-1.43) 1 (ref) 1.02 (0.80-1.32) 
HRa adjusted for age (95% CI) 1 (ref) 0.88 (0.70-1.12) 1 (ref) 1.12 (0.89-1.41) 1 (ref) 0.96 (0.74-1.24) 
HRa adjusted for age, grade, 
stage (95% CI) 
1 (ref) 0.85 (0.66-1.08) 1 (ref) 1.10 (0.79-1.26) 1 (ref) 1.07 (0.82-1.39) 
      
Abbreviations: Cum.= cumulative, CI= confidence interval, HR= hazard ratio, ref.= reference 
aHazard ratios from Cox regression analyses for the entire observation period 
 
